Vaccine against bovine leukemia virus
AssigneesUniversitéDe LièGe, Instituto Nacional De Tecnologia Agropecuaria
InventorsLuc Willems, Karina Trono
Life of this patent
Estimating the term…
Abstract
The invention relates to recombinant bovine leukemia viruses that have an attenuated phenotype and comprise a combination of at least two specific mutations. The invention also provides recombinant nucleic acids encoding such viruses, vectors comprising such nucleic acids, and host cells comprising such nucleic acids or vectors. The recombinant attenuated BLV viruses, recombinant nucleic acids, vectors and host cells allow for the preparation of improved vaccines, in particular vaccines suitable for the prophylactic treatment of BLV-associated diseases in subjects. The invention further provides methods for treating BLV-associated diseases in subjects and pharmaceutical compositions suitable for use in these methods.
Claims18
A recombinant attenuated BLV encoded by the plasmid as deposited under the Budapest Treaty with the Belgian Coordinated Collections of Microorganisms BCCM/LMBP Collection under accession number LMBP 8713 on Oct. 25, 2013.
A plasmid as deposited under the Budapest Treaty with the Belgian Coordinated Collections of Microorganisms BCCM/LMBP Collection under accession number LMBP 8713 on Oct. 25, 2013.
A recombinant nucleic acid encoding a recombinant attenuated BLV, wherein the recombinant nucleic acid comprises, consists essentially of or consists of the insert of the plasmid as deposited under the Budapest Treaty with the Belgian Coordinated Collections of Microorganisms BCCM/LMBP Collection under accession number LMBP 8713 on Oct. 25, 2013.
Dependencies are inferred from the claim text.